A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer.

Trial Profile

A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Ganitumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 09 Sep 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Sep 2010 Planned end date changed from 1 Jan 2013 to 1 Aug 2010 as reported by ClinicalTrials.gov.
    • 05 Jul 2010 Status changed from suspended to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top